Simeticone with aluminium hydroxide and magnesium hydroxide
Brand names: Asilone, Maalox Plus
This is a compound antacid combining the antifoaming agent simeticone with aluminium hydroxide and magnesium hydroxide, used for symptomatic relief of dyspepsia, heartburn and trapped wind.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Aluminium and magnesium hydroxides neutralise gastric acid to raise intragastric pH, while simeticone lowers the surface tension of gas bubbles to aid their dispersal; the combined magnesium and aluminium salts balance their opposing effects on bowel habit.
Prescribing in practice
- Antacids reduce the absorption of many drugs and should be separated in time from agents such as tetracyclines, quinolones, iron and certain other medicines; aluminium- and magnesium-containing products require caution in renal impairment owing to accumulation.
- Magnesium salts tend to cause diarrhoea and aluminium salts constipation, so bowel habit may shift depending on the balance.
- It is for short-term symptomatic use; persistent or alarm symptoms warrant investigation.
Monitoring
No routine monitoring is required for short-term use, but review symptom control and exercise caution with repeated use in renal impairment.
Counselling the patient
- Take after meals and at bedtime when symptoms occur.
- Leave a gap before or after other tablets, as antacids can stop them working properly.
- See your prescriber if symptoms persist, worsen or are accompanied by weight loss or difficulty swallowing.
Evidence & guidelines
Compound antacids provide established short-term symptomatic relief of dyspepsia, consistent with NICE dyspepsia guidance.
Reference: NICE CG184; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021